Pamela Foulds
Directeur Technique/Scientifique/R&D chez FREELINE THERAPEUTICS HOLDINGS PLC
Profil
Pamela Foulds is currently the Chief Medical Officer at Auregen Biotherapeutics SA and Freeline Therapeutics Holdings Plc.
Previously, she held the position of Chief Medical Officer at Aegerion Pharmaceuticals, Inc. and Auregen Biotherapeutics, Inc. Foulds received her undergraduate degree from Georgetown University and her doctorate from Georgetown University School of Medicine.
Postes actifs de Pamela Foulds
Sociétés | Poste | Début |
---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Directeur Technique/Scientifique/R&D | 01/11/2021 |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Pamela Foulds
Sociétés | Poste | Fin |
---|---|---|
AEGERION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Auregen Biotherapeutics, Inc.
Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies. | Directeur Technique/Scientifique/R&D | - |
Formation de Pamela Foulds
Georgetown University | Undergraduate Degree |
Georgetown University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 4 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Technology Services |
Auregen Biotherapeutics, Inc.
Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies. | Commercial Services |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |